Factors affecting direct-acting antiviral agents therapy among cases with hepatitis C virus infection in Zhejiang Province
10.19485/j.cnki.issn2096-5087.2026.03.007
- Author:
YANG Jiezhe
;
ZHOU Xin
;
JIANG Jun
;
XU Yun
;
CHAI Chengliang
;
CHEN Lin
;
CHENG Wei
- Publication Type:Journal Article
- Keywords:
hepatitis C;
direct-acting antiviral agents;
therapy;
influencing factor
- From:
Journal of Preventive Medicine
2026;38(3):246-250
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the factors affecting direct-acting antiviral (DAA) therapy among cases with hepatitis C virus (HCV) infection in Zhejiang Province, so as to provide evidence for optimizing local HCV prevention and treatment strategies and improving DAA treatment coverage.
Methods:Eight counties (cities, districts) in Zhejiang Province were selected as survey sites. Consecutive sampling was used to enroll HCV cases reported from November 2022 to June 2024. Demographic information, diagnosis and treatment status, DAA therapy, and awareness of relevant medical insurance policies were collected through questionnaire surveys. Factors affecting DAA therapy among cases with HCV infection were analyzed using a multivariable logistic regression model.
Results:A total of 412 questionnaires were distributed, and 404 valid questionnaires were collected, with an effective rate of 98.06%. There were 291 males (72.03%) and 113 females (27.97%). The median age was 49.00 (interquartile range, 11.00) years. A total of 303 cases received DAA therapy, with a proportion of 75.00%. Multivariable logistic regression analysis showed that HCV cases aged 40-<50 years (OR=3.469, 95%CI: 1.228-9.345) and with per capita monthly household income >3 000 yuan (>3 000-5 000 yuan, OR=3.198, 95%CI: 1.597-6.403; >5 000 yuan, OR=5.391, 95%CI: 2.230-13.033) had higher likelihood of receiving DAA therapy. HCV cases diagnosed in non-infectious disease departments (OR=0.334, 95%CI: 0.173-0.643), concerned about economic burden of DAA therapy (OR=0.309, 95%CI: 0.160-0.599), and unaware of HCV payment policy by disease type (OR=0.262, 95%CI: 0.111-0.622) had lower likelihood of receiving DAA therapy.
Conclusions:The proportion of DAA therapy among cases with HCV infection in Zhejiang Province is relatively high. Age, per capita monthly household income, department of diagnosis, concerns about DAA therapy, and medical insurance/payment policies are factors influencing DAA therapy among cases with HCV infection.
- Full text:2026110616113606158浙江省丙型病毒性肝炎病例直接抗病毒药物治疗的影响因素研究.pdf
